JLM-BioCity Pharma and Biotech Pitch Event

JLM-BioCity Pharma and Biotech Pitch Event
Wednesday, January 4th, 2023

JLM-BioCity is organizing an evening event for both Biomed and Pharma Startups pitching to a panel of leading investors:

• Dr Yael Gruenbaum-Cohen, Venture Partner, aMoon
• Ori Choshen, CEO, VLX Ventures
• Dr Goozy Hartog, Principal, Pontifax
• Marc Feiglin, Head of Innovative Technologies, Deerfield Management

During the event, the 6 folloowing startups will pitch to multiple investors and a live audience:

1. Cavos Biotech High-resolution drug targets for cancer
   [https://www.linkedin.com/company/cavos-biotech-ltd/about](Cavos Biotech)
2. Concentor BioPharma Drugs for Type 2 Diabetes
   https://www.concenterbiopharma.com/
3. ITAY& Biond Drug for Autism http://itayandbiond.com
4. Limobrain Drug Delivery System to the Brain
5. Tzofen Oncological Gene Engineering Viruses against Cancer.
   www.Tzofen-bt.com
6. Vitalunga Anti Aging Drug https://www.linkedin.com/company/vitalunga/

JLM-BioCity is delighted to announce this event is sponsored by Azrieli College of Engineering and, Atobe, Azrieli College's Startup Entrepreneurship Center.

Presentations will be in English.

The meeting will have networking that JLM-BioCity is famous for, both before and after the formal presentation. We will work to make introductions so that every participant will go away with at least 5 good leads!

Please RSVP as soon as possible.

NOTE: We ask you for a 20 NIS cash donation at the entrance to the event. The JLM-BioCity Team are all volunteers, but we have expenses to cover. Thank you for your donation in advance.

PLEASE FILL OUT IN HEBREW THE GOOGLE FORM TO GET ENTRANCE TO THE AZRIELI COLLEGE to https://forms.gle/uiNQFL9sACJLeWPt6

About the panelists:

• DR YAEL GRUENBAUM-COHEN, Venture Partner, aMoon
  Prior to joining aMoon, Yael was a General at Medison Ventures, leading licensing, investments, and strategic collaborations with global pharmaceutical companies and academic institutes. Before then Yael led medical affairs for the Rare Disease division at Medison Pharma. With academic degrees in molecular genetics (Ph.D., Postdoc) and a DMD from the Hebrew University of Jerusalem and the Weizmann Institute of Sciences
• ORI CHOSHEN, CEO, VLX Ventures
  Builds innovation platforms and establishes and invests in innovative startups in the biotech and computational biology industries. Prior to joining VLX Ventures, Ori served as VP of Business Development at Xenia VC and as a Director of Business Development at SanDisk, (NSDQ: SNDK) where he managed the Ecosystem Group. Ori joined SanDisk as part of the company’s $1.6 billion acquisition of M-Systems (NSDQ: FLSH) in 2006. Prior to this, Ori held business development and management positions at M-Systems and Hutchison’s global telecom group. Ori holds a B.A. in Philosophy, Cum Laude, and an LLB degree from Tel Aviv University as well as an MBA, Cum Laude, from the Solvay Business School in Brussels.
• DR GOOZY HARTOG, Principal, Pontifax
  Joined Pontifax in 2022 to co-manage our venture debt fund, as well as to manage and source pipeline deal flow. Also manages Pontifax’s venture debt portfolio and leads business development initiatives. Prior to joining Pontifax Goozy spent 5 years at Medison Ventures filling various strategy, investment, and BD roles. Goozy also spent 2 years at the Boston Consulting Group NYC and Tel Aviv offices, focusing on engagements with global pharmaceutical companies. Goozy obtained his Ph.D. in Neurobiology from the New York Medical College, studying the biochemistry of Post-Traumatic Stress Disorder.
• MARC FEIGLIN , Head, Innovative Technologies, Deerfield Management
  Joined the Firm in 2022 to work on the “Lab of the Future” project. Prior to joining Deerfield, Mr. Feiglin was a Senior Director, External Innovation, Corporate Development & Strategy at Thermo Fisher Scientific. Before that, Mr. Feiglin spent five years at Merck KGaA in various roles, most recently as Senior Director of Alliance Management & Partnerships, Electronic Materials. Mr. Feiglin holds a B.S. in Biology from the University of Michigan, and an M.B.A. jointly awarded by New York University, the London School of Economics and HEC Paris.